Shiv Srivastava, Ph.D.

Co-director, CPDR
Professor & Scientific Director

Shiv Srivastava, PhD is the Co-Director and Scientific Director at Center for Prostate Disease Research (CPDR) and holds Judd W. Moul Basic Science Chair in the Department of Surgery, Uniformed Services University of the Health Sciences (USUHS). Dr Srivastava is an established cancer researcher in a leadership position with a strong academic/administrative track record in the cancer biology and translational research. Dr. Srivastava's research contributions in the field of cancer biology and genetics with special focus on the fundamental mechanisms of oncogene and tumor suppressor gene alterations and prostate cancer basic and translational research have been recognized internationally.

Dr. Srivastava has developed a vigorous basic science and translational research program in prostate cancer and unique bio-resources. Dr. Srivastava's current research focuses on: (1) defining prostate cancer-specific gene/protein alterations and hormonal mechanisms using state-of-the-art gene expression profiling, positional cloning and functional genomics approaches (2) developing and evaluating novel technologies for improving diagnosis and prognosis of prostate cancer using blood and urine based prostate cancer-specific gene expression or proteomics profiles.

As the CPDR Scientific Director, Dr. Srivastava has played a central role in the successful outcome of the multi-disciplinary translational research effort between urologists, cancer biologists, pathologists, epidemiologists and bio-and medical informaticians. This synergy has been highlighted by the discovery of several high impact publications from the CPDR. One of the recent highlights of this effort is the 2005 discovery of ETS-Related Gene (ERG) as one of the most frequent proto-oncogenic alterations in prostate cancer cells. This observation is highly promising in the light of an independent report showing ERG as a common partner in a high frequency chromosomal translocation noted in prostate cancer. ERG alterations may in fact represent first potentially causal gene alteration of such a high frequency in prostate cancer. Translational utility (biomarker and therapeutic) of new prostate cancer specific gene alterations including ERG are currently under evaluation by Dr. Srivastava and his collaborators.

Dr. Srivastava has been the recipient of several research fellowships and grant awards including the Fogarty International Fellowship at the NIH, research grants from NIH, DoD, CaP Cure, USU and Georgetown University, as well as from the corporate partners. Dr. Srivastava has been actively involved in teaching and educating high school and college students, graduate students, medical students, postdoctoral fellows, and urology residents. Dr. Srivastava actively volunteers his scientific expertise to the international cancer research community by serving as a reviewer for leading cancer and prostate cancer journals and grant applications in the field of cancer molecular biology.